Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax TSLA Option Income Strategy ETF vs GeneDx Holdings Corp — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.9× YieldMax TSLA Option Income Strategy ETF's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax TSLA Option Income Strategy ETF for 43 Days and GeneDx Holdings Corp for 19 Days on average.
| TSLY | WGS | |
|---|---|---|
Market Cap | $697.51M | $2.02B |
Volume | 338,271 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $43.35 | $167.51 |
52-Week Low | $20.49 | $34.51 |
Typical Hold Time | 43 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $22.45, down 0.66% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent analysis highlights concerns about missing Tesla's upside potential. Support levels cluster around $22 with resistance at $23-24, while RSI indicators remain neutral.
The outlook remains mixed with high yield appeal balanced against structural limitations in capturing Tesla's gains. Key risks include Tesla's volatility regime changes and the ETF's option income strategy constraints. Recent analyst downgrades to Hold reflect diminished upside capture potential amid Tesla's extended capex cycle.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
